Geode Capital Management LLC Purchases 4,043 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Geode Capital Management LLC boosted its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 9.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,720 shares of the biotechnology company’s stock after acquiring an additional 4,043 shares during the quarter. Geode Capital Management LLC owned 0.81% of Atara Biotherapeutics worth $380,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ATRA. State Street Corp raised its stake in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the last quarter. FMR LLC raised its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics in the 2nd quarter worth about $79,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics during the 2nd quarter valued at about $53,000. Finally, Vestal Point Capital LP boosted its holdings in shares of Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 12,677 shares during the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ATRA shares. RODMAN&RENSHAW raised shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, December 20th. Canaccord Genuity Group boosted their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.75.

Atara Biotherapeutics Trading Down 5.9 %

ATRA opened at $15.55 on Monday. The firm’s 50 day simple moving average is $12.47 and its two-hundred day simple moving average is $9.89. The company has a market capitalization of $89.57 million, a PE ratio of -0.60 and a beta of 0.51. Atara Biotherapeutics, Inc. has a 1-year low of $6.50 and a 1-year high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the business posted ($16.50) earnings per share. Equities analysts forecast that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.